At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Nov 2, 2026 at 21:59 ET
Rhythm Pharmaceuticals amended its global license agreement with LG Chem for bivamelagon, replacing the low-to-mid-single-digit royalty with a 1% royalty and committing $350 million in additional fixed payments over four years. To fund this and its commercial/pipeline activities, Rhythm secured a $750 million term-loan facility led by KKR's HealthCare Royalty and Blackstone, with an initial $250 million draw expected on November 6, 2026.
- Amended LG Chem agreement: fixed payments of $350M over four years ($70M within 15 business days, $100M in Sep 2027, $100M in Sep 2028, $80M in Sep 2029).
- Royalty reduced to 1% on global net sales of Rhythm's MC4R portfolio, starting Jan 1, 2029 or first commercial sale of bivamelagon.
- Additional milestone payment of up to $200M if annual global net sales of MC4R portfolio reach $3B.
- Secured $750M term-loan facility led by KKR's HealthCare Royalty and Blackstone; $500M committed, $250M initial draw at closing expected Nov 6, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access